Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

Joseph M. Flynn, Jeffrey A. Jones, Amy J. Johnson, Leslie A. Andritsos, Kami J. Maddocks, Samantha Jaglowski, J Hessler, Michael R. Grever, E. Im, Haiyu Zhou,

Leukemia · 2015 · 117 citations · 36 references

DOIFull text

Open access

Concepts

References

36